Expression of the human multidrug resistance 1 gene (MDR1), which encodes the P-glycoprotein transmembrane efflux pump, has been associated with treatment failure of some leukemias, primarily acute myeloid leukemia (AML). To elucidate the epigenetic events associated with overexpression of MDR1 in AML, we analyzed the methylation status of a 2000 bp region within the MDR1 locus using a bisulphite genomic sequencing technique. A CpG-rich domain, approximately 1 kb in size, encompasses the promoter region, exon I, and intron I. This domain was found to be relatively unmethylated in five out of six primary and cultured human hematopoietic cells, as well as five out of six AML patient samples, independent of the MDR1 phenotype. The data suggest that the methylation status of the CpG-rich domain does not act as a 'switch' to regulate expression of the MDR1 gene. In addition, we found an upstream Alu repeat sequence to be unmethylated in three out of five cultured hematopoietic cell lines, both MDR1 expressing and non-expressing. However, analysis of primary CD8-positive T cells and AML patient samples revealed dense methylation of this region which is consistent with methylation of Alu repeat sequences observed in somatic tissues.
Introduction
Multidrug resistance is a major impediment to the successful treatment of cancer with chemotherapeutic agents. 1 One mechanism associated with multidrug resistance in hematopoietic tumors, primarily acute myeloid leukemia (AML), involves the P-glycoprotein transporter encoded by the human multidrug resistant 1 gene (MDR1 gene).
2 P-glycoprotein is an energy-dependent transmembrane pump that facilitates the cellular efflux of various substances, including chemotherapeutic drugs.
3 Expression of MDR1 mRNA and the presence of P-glycoprotein in leukemic blast cells have been associated with treatment failure of de novo as well as treated and relapsed AML patients. 4, 5 Some knowledge about MDR1 gene regulation has been gained at the level of transcriptional control, [6] [7] [8] [9] but very little is known about the chromatin organization of the MDR1 locus. It is evident that higher order chromatin structure plays a crucial role in gene regulation, whereby actively transcribed genes are characterized by an open chromatin configuration. [10] [11] [12] DNA elements, referred to as CpG islands, are distinct regions involved in the regulation of chromatin structure and gene expression. 13, 14 CpG islands are generally underacetylated, lack histone H1 and have a nucleosome-free region conferring an open state of the chromatin. 15 CpG islands, located at the 5Ј ends of all housekeeping genes and approximately 40% of tissue-specific genes, are generally unmethylated regardless of the level or pattern of transcription of their associated genes. 16 Exceptions include methylated CpG islands of silenced genes associated with imprinting, Xchromosome inactivation, fragile-X syndrome, and tumorigenesis. [17] [18] [19] [20] [21] A CpG-rich domain, approximately 1 kb in size, encompasses the MDR1 promoter region, exon I, and intron I. Several contradictory preliminary reports have associated MDR1 gene expression with either low or high levels of methylation in this CpG-rich domain in various primary and cultured cell types. [22] [23] [24] [25] It has been suggested that the multidrug resistance phenotype may be acquired as a result of changes in methylation patterns of the MDR1 promoter which act as a 'switch' for MDR1 gene expression. 26 By using mouse L cells transfected with YAC clones containing the human MDR1 locus, Kusaba et al 27 concluded that hypermethylation inactivated the MDR1 promoter. Another study suggests that activation of the MDR1 gene is accompanied by demethylation of specific CpG sites within the promoter region and intron I. 28 The purpose of this study was to determine whether aberrant MDR1 expression levels in AML patient samples can be associated with methylation changes in the MDR1 locus. By using a bisulphite genomic sequencing technique, 29 we determined the methylation status of a 2000 bp region including an upstream Alu repeat sequence and a CpG-rich domain encompassing the MDR1 promoter region, exon I, and intron I. We examined various hematopoietic cell lines that have not been drug selected as well as leukemic blast cells isolated from adult de novo AML patients. These patients were newly diagnosed with AML and had never received prior therapy. All the samples used in this study have been well characterized in terms of MDR1 expression levels by RT-PCR and by flow cytometry analysis. 6, 28, [30] [31] [32] [33] [34] [35] [36] [37] Methylation analysis of the MDR1 gene will help elucidate the epigenetic events related to elevated MDR1 expression levels in AML.
Materials and methods

Cell culture of non-drug selected human hematopoietic cells
The following hematopoietic tumor cell lines were grown in RPMI 1640 containing 10% calf serum: K562 (erythroid leukemia) (provided by Dr SJ Collins, FHCRC), U937 (myelomonocytic), and HL60 (promyelocytic leukemia). The cell line KG-1 (acute myelogenous leukemia) was grown in Iscove's medium containing 10% calf serum. The cell line 8226/S (multiple myeloma) was grown in RPMI 1640 containing 5% fetal bovine serum and was provided by Dr WS Dalton (Moffitt Cancer Center, Tampa, FL). All media were supplemented with 2 mm l-glutamine, 50 units/ml penicillin, and 50 g/ml streptomycin. CD8-positive human T cells from a 911 normal, healthy individual were provided by Dr S Riddell, FHCRC. 38 
AML patient samples
Leukemic samples from adult patients diagnosed with de novo AML were provided from the Southwest Oncology Group Leukemia Repository at UNM (SWOG protocol 8600). These samples were obtained from newly diagnosed AML patients who had never received prior therapy and who had never been diagnosed with antecedent myelodysplasia. All samples were obtained with appropriate informed consent and were anonymized for this study. After initial sample receipt, leukemic blasts were enriched over Ficoll-Hypaque (Pharmacia, Piscataway, NJ, USA) and cryopreserved as sterile, viable cell suspensions. Leukemic blasts were assessed for MDR1 protein expression and functional efflux using a highly sensitive multicolor flow cytometric assay as previously described.
36 MDR1 expression was also assessed using a sensitive and specific PCR assay for MDR1 mRNA expression as previously described. 37 For the purpose of this study, genomic DNAs were prepared from these leukemic samples after sample thawing by standard phenol/chloroform methods. Enriched blast contents of AML patient samples were as follows: patient A = 90%, patient B = 77%, patient C = 80%, patient D = 100%, patient E = 95% and patient F = 80%. FAB classification of these patient samples is as follows: patient A = M5a, patient B = M4, patient C = M4, patient D = M2, patient E = M1 and patient F = M4.
Sodium bisulphite conversion reaction
Genomic DNA was isolated from the hematopoietic tumor cell lines and from CD8-positive T cells using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). Genomic DNA from AML patient samples was purified by a standard phenol/chloroform method. Genomic DNA from primary and cultured cells and AML patient samples was subjected to the sodium bisulphite conversion reaction. During this reaction, cytosine residues were converted to uracil residues with the exception of 5-methylcytosine residues which remained unreactive. 29 Following PCR amplification, the regions of interest were sequenced and analyzed for cytosine residues representing previously methylated residues in the genome. Approximately 0.25 g genomic DNA (previously digested with EcoRI) containing 0.1 mg/ml tRNA was denatured in freshly prepared 0.3 m NaOH in a 100 l reaction volume and incubated at 42°C for 45 min followed by an additional incubation at 100°C for 2 min. A fresh solution of 4.25 m sodium bisulphite, pH 5.0, (Sigma, St Louis, MO, USA) containing 1 mm hydroquinone (Sigma) was prepared by gentle mixing and warmed to 55°C. Final concentrations of 3.4 m sodium bisulphite and 0.8 mm hydroquinone were added to the 100 l denatured DNA to a final volume of 500 l. The reaction was overlaid with mineral oil and incubated in the dark at 55°C for 6 h. The sample was recovered from under the oil, and unbound bisulphite was removed using the Wizard DNA Clean-Up System (Promega, Madison, WI, USA). The DNA was desulphonated with freshly prepared NaOH (0.3 m final concentration) by incubation at 37°C for 20 min. NaOH was removed by using a sephadex G-50 gel filtration column (Sigma).
PCR
Primers were designed to amplify the sense-strand of bisulphite-converted DNA. The numbering of the nucleotides corresponds to genomic MDR1 DNA sequence relative to the transcriptional start site (GenBank accession M57450 and X58723). 39, 40 Due to inherent nicking of the DNA during the bisulphite conversion reaction, the regions analyzed (PCR 1, PCR 2 and PCR 3) were limited to 500 bp or less. 
Cloning and sequencing of PCR products
The semi-nested PCR products representing regions PCR 1, PCR 2 or PCR 3 were electrophoresed on a 1.4% agarose gel and isolated using DE81 anion exchange paper. Fragments were subcloned into the plasmid pCR2.1 using the TA Cloning Kit (Invitrogen). DNA was isolated from clones using the QIAprep Spin Miniprep Kit (Qiagen, Chatsworth, CA) and sequenced using the ABI PRISM dye terminator TaqFS cycle sequencing ready reaction kit (Perkin Elmer). Sequence data were collected on either a model 377 or model 373S DNA sequencer (Perkin Elmer-ABio Systems).
Results
Methylation status of the MDR1 CpG-rich domain in hematopoietic tumor cell lines
A diagram of the MDR1 promoter region, including a CpGrich domain, and an upstream Alu repeat sequence is illustrated in Figure 1 . The region bordered by nucleotides −270 and +650 approximates the boundaries of a CpG-rich domain that by definition has a guanine (G) and cytosine (C) content that is greater than 50%, an observed to expected CpG ratio that is greater than 0.6, and a length that exceeds 200 bp. 41 The MDR1 CpG-rich domain is 59%, 0.74, and 920 bp, respectively. Genomic DNA was isolated from the human hematopoietic tumor cell lines 8226/S, HL-60, U937, K562 and KG-1, primary CD8-positive T cells, and AML leukemic blast cells was analyzed for methylation patterns by a bisulphite genomic sequencing technique. The DNA regions amplified by PCR were denoted as PCR 1, PCR 2 and PCR 3 and were subcloned and subsequently sequenced. The cell lines had been previously characterized both by our laboratory and by other groups as either MDR1 non-expressing (MDR1−) (8226/S, HL-60 and U937), or as MDR1 expressing (MDR1+) (K562 and KG-1) by RT-PCR and by fluorescent labeling with a P-glycoprotein-specific monoclonal antibody. 6, 28, [30] [31] [32] [33] [34] [35] The MDR1 expression levels were verified by RT-PCR prior to performing the methylation analysis (data not shown). Figure 2 shows the methylation status of the MDR1 CpGrich domain (regions PCR 2 and PCR 3) in various hematopoietic cell lines. The domain appears to be relatively unmethylated in the cell lines 8226/S (MDR1−) and KG-1 (MDR1+). The cell lines HL-60 (MDR1−) and K562 (MDR1+) were unmethylated in region PCR 2 but exhibited variable methylation patterns in the downstream region PCR 3. In contrast, the cell line U937 (MDR1−) was almost completely methylated in regions PCR 2 and PCR 3. MDR1 gene silencing in these cell lines does not strictly correlate with methylation of the CpG-rich domain. To control for aberrant global methylation patterns in these cell types, we analyzed the methylation status of the constitutively active deoxycytidine kinase gene (dCK). 42, 43 All the cell lines were completely unmethylated in the dCK CpG island (data not shown).
Methylation status of the MDR1 CpG-rich domain in AML patient samples and CD8 positive T cells
Genomic DNA from de novo AML leukemic blast cells was subjected to the bisulphite conversion reaction. Patient samples B (MDR1−), C (MDR1−) and F (MDR1+) were unmethylated in regions PCR 2 and PCR 3 (Figure 3a and b) . Patient A (MDR1−) was unmethylated in region PCR 2 but displayed variable methylation patterns in region PCR 3. In these MDR1 non-expressing AML samples, methylation does not correlate with MDR1 gene silencing. Patient D (MDR1+) was completely methylated in one out of four PCR subclones in region PCR 2 and was unmethylated in region PCR 3. Patient E (MDR1+) displayed complete methylation of all four PCR subclones tested in region PCR 2 and was unmethylated in region PCR 3.
We also analyzed the CpG-rich domain in CD8-positive T cells to determine whether the methylation status of MDR1 in hematopoietic tumor cell lines and AML patient samples reflect the methylation status in normal, primary hematopoietic cells. CD8-positive T cells have been shown to express MDR1 mRNA by RT-PCR as well as a functional P-glycoprotein cell surface transporter. 31, 44 Similar to the cell lines, CD8-positive T cells were relatively unmethylated in regions PCR 2 and PCR 3 (Figure 3a and b) although region PCR 3 showed several CpG sites that were consistently methylated. Methylation analysis of the control dCK gene in CD8-positive T cells and in AML patient samples C and E revealed complete unmethylation of the dCK CpG island (data not shown). AML patient samples A, B, D and F were not analyzed for dCK methylation status.
Methylation status of the upstream Alu repeat sequence
The methylation status was determined for a CG-rich Alu repeat sequence (−1402/−1088) located approximately 1 kb upstream of the MDR1 promoter region (Figure 1 ). The MDR1 non-expressing cell line, 8226/S, and the MDR1 expressing cell lines, K562 and KG-1, were relatively unmethylated in the Alu repeat sequence (region PCR 1) (Figure 4a ). In contrast, U937 and HL-60 cell lines, CD8-positive T cells, and all three tested AML patient samples (B, C and E) exhibited methylation in the Alu repeat sequence which was independent of the MDR1 phenotype (Figure 4a and b) .
Discussion
Expression of the human MDR1 gene encoding the P-glycoprotein transporter in leukemic blast cells has been correlated with poor prognosis of patients diagnosed with AML. 4, 5 We have analyzed the methylation status of the MDR1 locus in Figure 2 Methylation status of the MDR1 CpG-rich domain in hematopoietic tumor cell lines. Cultured cell analysis of regions defined as PCR 2 and PCR 3 (MDR1 CpG-rich domain) is shown in (a) and (b), respectively. For each cell line, four to eight subclones of the PCR products were analyzed (gray bars). Cell lines: 8226/S (multiple myeloma), U937 (myelomonocytic), HL60 (promyelocytic leukemia), K562 (erythroid leukemia) and KG-1 (acute myelogenous leukemia). Black spaces: methylated cytosines, white spaces: non-methylated cytosines, open circles: undetermined. MDR1 expressing cells (MDR1+); MDR1 non-expressing cells (MDR1−). Asterisks (*) indicate CCGG sequences that are recognized by methylation-sensitive and -insensitive enzymes (MspI, HapII or HpaII). These sites are located in (a) at nucleotides −112, −107 and −58, and in (b) at +343 and +435, relative to the transcriptional start site.
various non-drug selected hematopoietic cell types to identify regulatory mechanisms related to elevated expression levels of P-glycoprotein in AML. By using the bisulphite sequencing technique, we analyzed 63 CpG sites spanning 2000 bp which exceeds the information obtained by the traditional use of methylation-sensitive and -insensitive restriction enzymes and Southern hybridization analysis. The purpose of this study was to determine whether the methylation of the CpG sites in the MDR1 locus correlated with P-glycoprotein expression in AML patients. We used samples from newly diagnosed AML patients prior to their treatment with chemotherapeutic drugs. Expression of the MDR1 gene in the patient samples was therefore unrelated to the patient treatment status.
We determined that the CpG-rich domain (−270/+650), which encompasses the MDR1 promoter, exon I and intron I regions, is relatively unmethylated in most cell types regardless of the MDR1 phenotype. This domain, approximately 1 kb in size, has a G and C content of 59% and an observed to expected CpG ratio of 0.74 which meets the criteria for a CpG-rich island. 41 Our working model states that this domain consists of a conserved unmethylated CpG island. (PCR 2) adjacent to a more variably methylated downstream CG-rich sequence (PCR 3). The CpG island of the p16/CDKN2 gene exemplifies a CG-rich region in which methylation of exon I but not exon II correlates with gene silencing. 45 Since the MDR1 region PCR 2 appears to maintain an overall unmethylated state as compared to region PCR 3 in cultured and primary cells (Figures 2 and 3) , we propose to denote this region as a conserved CpG island. The MDR1 non-expressing cell line, U937, is an exception to this finding which exhibited methylation of the entire CpG-rich domain. In this cell line, methylation may be responsible for MDR1 gene silencing.
Of particular interest are the results from AML samples from patients D and E, both of which express the MDR1 gene. In these samples, the MDR1 promoter and exon I sequences (region PCR 2), but not intron I sequences (region PCR 3), were completely methylated in one out of four subclones for patient D, and in all four subclones analyzed for patient E (Figure 3a and b) . It is possible that MDR1 is activated due to a rearrangement in the MDR1 locus in some AML patient 46 have demonstrated that increased MDR1 expression can occur by MDR1 gene rearrangements in acute lymphoblastic leukemia (ALL) samples as well as hematopoietic cell lines. A subsequent study provided evidence of allele switching (predominant MDR1 gene expression from a single allele) during the development of acquired drug resistance in leukemias. 47 Perhaps patient D represents an example in which the aberrantly methylated allele is repressed and the unmethylated allele is responsible for the MDR1 overexpression by allele switching. Patient E may represent an incidence in which the unmethylated allele cannot be detected by PCR due to MDR1 gene rearrangement in region PCR 2. These possibilities are currently being examined in presentation and relapsed AML patient samples.
samples. Mickley et al
We investigated whether the methylation status of a CGrich Alu repeat sequence, in close proximity to the MDR1 promoter, correlated with MDR1 gene expression in hematopoietic cells and AML patient samples. Alu repeat sequences in somatic tissues, such as spleen and brain, have been found to be nearly completely methylated. [48] [49] [50] However, examples of unmethylated Alu repeat sequences have been observed in primate germ cells suggesting their involvement in development processes such as genomic imprinting or maintaining differences in male and female meiosis. 48, 51 Our studies showed the MDR1 Alu repeat sequence to be unmethylated in three out of five hematopoietic tumor cell lines, both MDR1 expressing and non-expressing (Figure 4a ). However, CD8-positive T cells, as well as all three AML patient samples examined, exhibited dense methylation of the Alu repeat sequence which was independent of the MDR1 expression state (Figure 4b ). These results suggest that the Alu repeat sequence is aberrantly unmethylated in 8226/S, K562 and KG-1 cell lines. We conclude that this region is intrinsically methylated as are most Alu repeat sequences in somatic tissues.
We analyzed the MDR1 gene in normal and leukemic cells in order to determine whether MDR1 expression is associated with methylation changes in the MDR1 locus. Our studies show that the MDR1 CpG-rich domain is relatively unmethylated in five out of six hematopoietic tumor cell lines, which is independent of the MDR1 expression state. In these cell types, MDR1 gene silencing does not correlate with methylation of the CpG-rich domain. This finding was also evident in the limited number of AML patient samples examined. Further studies are required to examine potential MDR1 gene rearrangements in AML as indicated by the complete methylation of region PCR 2 in patient E. Therefore, we conclude that the methylation status of the CpG rich domain does not act as a 'switch' to regulate expression of the MDR1 gene.
